ImmuCell Q3 product sales rise 46% to $8 million, preliminary results show
Bitget2026/10/12 20:06- ImmuCell posted preliminary unaudited Q3 2026 sales of $8 million, up 46% from a year earlier.
- Domestic sales reached $6.9 million, up 29.2% year over year.
- Nine-month sales totaled $25.6 million, a 27.8% increase from the prior-year period.
- Tri-Shield sales rose 51% year over year; Dual-Force increased 36%; functional feed line grew 37%.
- Early sales reporting will be discontinued; revenue will be reported with full quarterly financial results going forward.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Edges Higher as Treasury Yields, Dollar Ease -- Market Talk
Morgan Stanley is tactically bullish on BHP (BHP.US): Two major copper mine catalysts may ignite the stock price in the next two months
Morgan Stanley maintains an "Overweight" rating on BHP Group, with an "attractive" industry outlook, and sets a target price of AUD 69.00 for its shares listed in Australia.
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
Crypto prices
More
